{
    "clinical_study": {
        "@rank": "119431", 
        "arm_group": {
            "arm_group_label": "Ipilimumab and Degarelix With Radical Prostatectomy", 
            "arm_group_type": "Experimental", 
            "description": "Week 1: Degarelix 240 mg SQ injection and Ipilimumab at 10 mg/kg intravenously (IV). Surgery Radical prostatectomy (RP)will be performed during week 3 \u00b1 1 week or after recovery to grade \u2264 1 adverse events experienced during the induction period related to treatment. Continued Androgen Depletion and Ipilimumab  Weeks 5, 9, 13, 17, 21, 25, and 29: Degarelix 80 mg SQ\nWeek 11, 14, 17 or after sufficient wound healing and recovery post RP:\nIpilimumab 10mg/kg IV Follow-up Twelve week intervals until Week 87."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to find out what effects, good and/or bad, taking ipilimumab\n      with degarelix before surgery to remove the  prostate, followed by more degarelix and\n      ipilimumab after the surgery, will have on prostate cancer."
        }, 
        "brief_title": "Ipilimumab and Degarelix With Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer", 
        "condition": "Metastatic Castration Sensitive Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Target Population Patients with castration-sensitive oligometastatic prostate cancer who\n        have not received primary local therapy (radiation or surgery), and no more than 2 months\n        of prior androgen deprivation therapy.\n\n          -  The subject must be age 18 or older, and be willing and able to provide informed\n             consent.\n\n          -  The subject must have histologically confirmed adenocarcinoma of the prostate with\n             tissue confirmation at selected study site.\n\n          -  The subject must have newly diagnosed prostate cancer with a metastatic site(s).\n\n          -  The subject must have \u2264 10 bony metastatic lesions detected by nuclear medicine bone\n             scan.\n\n          -  Distant metastatic lymph node(s) (e.g., retroperitoneal or non-regional pelvic lymph\n             nodes) are allowed\n\n          -  Regional pelvic lymph nodes (as per AJCC Cancer Staging [7th edition]) will be\n             considered a metastatic site if greater than 1.5cm in shortest dimension.\n\n          -  The subject must have Karnofsky performance status of 80-100.\n\n          -  Normal organ function with acceptable initial laboratory values:\n\n               -  WBC \u2265 2000/\u03bcL\n\n               -  ANC \u2265 1000/ \u03bcL\n\n               -  Platelets \u2265 75 x 103/\u03bcL\n\n               -  Creatinine \u2264 2.0 x ULN\n\n               -  AST/ALT \u2264 2.5 x ULN\n\n               -  Bilirubin \u2264 1.5 x ULN (except patients with Gilbert's Syndrome, who must have a\n                  total bilirubin less than 3.0 mg/dL)\n\n          -  No active or chronic infection with HIV, Hepatitis B or Hepatitis C (negative\n             screening tests required).\n\n          -  The subject must be deemed to be medically fit for radical prostatectomy by the\n             attending urologic surgeon at the selected study site.\n\n          -  Men of fathering potential must be using an adequate method of contraception to avoid\n             conception throughout the study [and for up to 26 weeks after the last dose of\n             ipilimumab] in such a manner that the risk of pregnancy is minimized.\n\n        Exclusion Criteria:\n\n          -  Any other malignancy from which the patient has been disease-free for less than 5\n             years, with the exception of adequately treated and cured basal or squamous cell skin\n             cancer or superficial bladder cancer\n\n          -  Major surgery within 4 weeks of enrollment (Week 1 Visit).\n\n          -  Current or prior radiation therapy to the prostate Prior radiation to a metastatic\n             site (e.g., palliative radiation) is allowed..\n\n          -  More than 5 months of prior hormonal therapy (e.g., gonadotropin hormone releasing\n             analogs, megestrol acetate, or casodex) . There is no washout period required for\n             GnRH analogs. A two week washout is required for megestrol or anti-androgen.\n\n          -  Prior use of an 5 alpha reductase inhibitor is allowed (no limit on duration of use),\n             however a two week washout is required.\n\n          -  No prior ketoconazole, abiraterone acetate, or enzalutamide for the treatment of\n             prostate cancer.\n\n          -  Current or prior investigational therapies for prostate cancer, or chemotherapy\n             administered with the intent to treat prostate cancer.\n\n          -  Concomitant therapy with any other experimental drug.\n\n          -  Autoimmune disease: Patients with a history of inflammatory bowel disease, including\n             ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients\n             with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic\n             progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune\n             vasculitis [e.g., Wegener's granulomatosis]); motor neuropathy considered of\n             autoimmune origin (e.g., Guillain-Barre syndrome and myasthenia gravis).\n\n          -  Any underlying medical or psychiatric condition, which in the opinion of the\n             investigator will make the administration of ipilimumab hazardous or obscure the\n             interpretation of AEs, such as a condition associated with frequent diarrhea.\n\n          -  Patients with underlying heart conditions who are deemed ineligible for surgery.\n\n          -  Any non-oncology vaccine therapy used for prevention of infectious diseases (for up\n             to 1 month before or after any dose of ipilimumab).\n\n          -  Note: Inactivated vaccines are allowed at any time on study.\n\n          -  A history of prior treatment with ipilimumab or prior CD137 agonist or CTLA-4\n             inhibitor or agonist.\n\n          -  Concomitant or prior therapy with any of the following: IL-2, interferon, or other\n             nonstudy immunotherapy regimens; immunosuppressive agents; ; or chronic use of\n             systemic corticosteroids within 6 weeks of study entry.\n\n          -  Persons of reproductive potential unwilling to use an adequate method of\n             contraception throughout treatment and for at least 26 weeks after ipilimumab is\n             stopped.\n\n          -  Patients who have had a history of acute diverticulitis, intra-abdominal abscess, GI\n             obstruction and abdominal carcinomatosis which are known risk factors for bowel\n             perforation."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "53", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02020070", 
            "org_study_id": "13-134"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ipilimumab and Degarelix With Radical Prostatectomy", 
                "intervention_name": "Degarelix", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ipilimumab and Degarelix With Radical Prostatectomy", 
                "intervention_name": "Ipilimumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ipilimumab and Degarelix With Radical Prostatectomy", 
                "intervention_name": "Radical Prostatectomy", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Ipilimumab", 
            "Degarelix", 
            "Radical Prostatectomy", 
            "13-134"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": {
            "contact": {
                "last_name": "Karen Autio, MD", 
                "phone": "646-422-4632"
            }, 
            "contact_backup": {
                "last_name": "Howard Scher, MD", 
                "phone": "646-422-4330"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "Memorial Sloan Kettering Cancer Center"
            }, 
            "investigator": {
                "last_name": "Karen Autio, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Study Combining Ipilimumab and Degarelix With Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer", 
        "overall_contact": {
            "last_name": "Karen Autio, MD", 
            "phone": "646-422-4632"
        }, 
        "overall_contact_backup": {
            "last_name": "Howard Scher, MD", 
            "phone": "646-422-4330"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Karen Autio, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "An undetectable PSA at 12 and 20 months from the start of treatment among patients with non-castrate (> 150 ng/ml) levels of testosterone. An undetectable PSA is defined as PSA \u22640.05 ng/mL.", 
            "measure": "undetectable PSA", 
            "safety_issue": "No", 
            "time_frame": "at 12 and 20 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02020070"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Progression-free survival (PFS) is a composite endpoint defined as disease progression in bone or soft-tissue, symptoms, or death measured from study entry. Progression in soft tissue will be measured by modified RECIST per PCWG2..", 
                "measure": "progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Overall survival is defined as death from any cause measured from study entry.", 
                "measure": "overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Safety will be evaluated for all treated patients using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 (http://ctep.cancer.gov). Safety assessments will be based on medical review of AE reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests.", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Ferring Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}